BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Pharmaceuticals, Inc. announced it will release its financial results for the third quarter of 2026 on November 4, 2026, followed by a conference call and webcast.
Stocks · News reference
FDA Approves BioCryst Pharma’s sNDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Adults And Adolescents Aged 12 Years And Older
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets
BioCryst Pharmaceuticals received U.S. FDA approval for its new 150 mg oral pellet formulation of ORLADEYO (berotralstat) for the prevention of hereditary angioedema (HAE) attacks.
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
BioCryst Pharmaceuticals announced FDA approval of ORLADEYO 150 mg oral pellets for adults and adolescents aged 12 and older with hereditary angioedema (HAE). The new pellet formulation provides an alternative to capsules for patients with difficulty swallowing or those who prefer pellet administration. ORLADEYO remains the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, with clinical data showing 91% attack-rate reduction at 96 weeks.